目的:观察在高血压心脏病的治疗中 ,应用厄沙贝坦的临床疗效. 方法:选取2014年3 月~2015年3 月之间我院收治的高血压心脏病患者100例 ,将其随机均分为两组.对照组单纯采用氢氯噻嗪治疗 ,观察组在此基础上加用厄沙贝坦治疗 ,比较两组治疗前后的血压变化情况 ,评价临床疗效.结果:治疗前两组患者的血压值无显著差异 ,治疗后 ,观察组的舒张压和收缩压均 ,明显降低 ,而且低于对照组 ,差异显著 ,P< 0 .05 ;对照组患者治疗的总有效率为80 .0% ,小于观察组(97 .0% ) ,差异显著 ,P<0 .05.结论:在应用氢氯噻嗪治疗高血压心脏病的基础上 ,加用厄沙贝坦 ,可以有效降低患者的血压 ,改善临床疗效 ,值得推广.

Objective:To analyze the risk factors for acute cerebral infarct progression in posterior circulation(ACIPPC)and predicting function of plasma MMP-9.Methods:In this study we focused on ACIPPC and compared factors between ACIPPC and N-ACIPPC by single factor analysis,and sieved the independent risk factors for ACIPPC by logistic(Forward:Wald)analysis and demonstrated the predicting role of plasma MMP-9 to the infarction volume of ACIPPC by linear correlation and regression analysis.Results:Single factor analysis showed that hypertension history,diabetes mellitus history,dysphagia,neurological severity,blood glucose and plasma MMP-9 were significantlt different between ACIPPC and N-ACIPPC(P0.05).Logistic regression analysis indicated that blood glucose,neurological severity and plasma MMP-9 were independent risk factors for ACIPPC.Linear correlation and regression analysis manifested that plasma MMP-9 was a predicting factor for the DWI volume of ACIPPC patients.Conclusion:ACIPPC results from multi-factors,while blood glucose,neurological severity and plasma MMP-9 are independent risk factors for ACIPPC,and plasma MMP-9 may be a predicting factor for the brain stroke volume of DWI in ACIPPC patients.